Cargando…

Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?

Detalles Bibliográficos
Autor principal:	Kumar, Naveen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Uroscan
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555569/ https://www.ncbi.nlm.nih.gov/pubmed/34759535 http://dx.doi.org/10.4103/iju.iju_288_21

Ejemplares similares

Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial
por: Tarigopula, Vivek
Publicado: (2022)

CheckMate 214 trial: Immune checkpoint regulators for advanced renal cell carcinoma
por: Jena, Rahul
Publicado: (2020)

POUT trial: Perioperative chemotherapy in upper tract urothelial carcinoma – A standard of care?
por: Ranjan, Satish Kumar
Publicado: (2020)

Adjuvant intravesical chemohyperthermia or conventional chemotherapy in an era of bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer: The HIVEC-II trial
por: Bhargava, Priyank
Publicado: (2023)

Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial
por: Witjes, Johannes Alfred, et al.
Publicado: (2022)

Role of atezolizumab therapy combined with platinum-based chemotherapy in untreated metastatic urothelial carcinoma – The new landscapes (IMvigor130 trial)
por: Misra, Ankit
Publicado: (2021)

Nectin-4 inhibitors: An ace up our sleeve against advanced urothelial carcinoma
por: Kumaraswamy, Santosh
Publicado: (2021)

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial
por: Tomita, Yoshihiko, et al.
Publicado: (2022)

KEYNOTE-564: Adjuvant immunotherapy for renal cell carcinoma
por: Pandey, Abhishek
Publicado: (2022)

First-line maintenance immunotherapy in advanced urothelial cancers: Practice changing implications of the JAVELIN bladder 100 trial
por: Kumaraswamy, Santosh
Publicado: (2021)

Can early salvage radiotherapy replace adjuvant radiotherapy as the new standard of care for high-risk postradical prostatectomy patients?
por: Pandey, Abhishek
Publicado: (2021)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

Thulium laser versus standard transurethral resection of the prostate: A randomized prospective trial
por: Dubey, Deepak, et al.
Publicado: (2008)

What happens to the patients with muscle-invasive bladder cancer who refuse cystectomy after neoadjuvant chemotherapy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

PROFOUND trial –a new era in targeted therapeutics for prostate carcinoma
por: Tosh, Jyoti Mohan
Publicado: (2022)

Prognostic stratification of renal cell carcinoma using a pathological triad of microvascular invasion, Fuhrman's grade and tumor size
por: Prakash, Gagan, et al.
Publicado: (2007)

What is the role of adjuvant chemotherapy in locally advanced and lymph node-positive bladder cancer after radical cystectomy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

Does antenatal pelvic floor muscle training prevent stress urinary incontinence in primi-gravidae?
por: Gupta, Gaurav, et al.
Publicado: (2009)

Pharmacological prophylaxis for venous thromboembolism: Is it time to change the gold standard?
por: Kumaraswamy, Santosh
Publicado: (2021)

Pembrolizumab in bacillus Calmette-Guérin unresponsive nonmuscle-invasive bladder cancer; a difficult to treat disease (KEYNOTE-057)
por: Kumar, Bhuwan
Publicado: (2021)

Is lap nephrectomy superior to open? A randomized trial
por: Kumar, Anup, et al.
Publicado: (2008)

Comparison of multiparametric ultrasound versus multiparametric magnetic resonance imaging for diagnosis of carcinoma prostate: The CADMUS trial
por: Tarigopula, Vivek
Publicado: (2022)

HERO trial: A rescue from injectable androgen deprivation therapy
por: Ranjan, Satish Kumar
Publicado: (2021)

TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
por: Kumar, Gautam
Publicado: (2020)

Fluorodeoxyglucose-positron emission tomography/computed tomography-based chemotherapy dosage adjustment in seminoma: The GETUG SEMITEP trial
por: Dheeroo, Dheeraj Kumar
Publicado: (2022)

LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis
por: Kumar, Gautam
Publicado: (2020)

Role of simultaneous fine needle aspiration cytology of palpable inguinal lymph node and primary tumor biopsy in carcinoma of the penis
por: Khattar, Nikhil, et al.
Publicado: (2007)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Is there a better indicator for predicting the outcome of trial without catheter?
por: Shanmugasundaram, R., et al.
Publicado: (2007)

Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
por: Singh, Kirti
Publicado: (2023)

Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial
por: Singh, Kirti
Publicado: (2022)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020)

PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?
por: Gaur, Abhay Singh
Publicado: (2022)

PROMPTS Trial: Screening spinal magnetic resonance imaging in castration-resistant prostate cancer
por: Pattnaik, Soumya Shivasis
Publicado: (2023)

Temsirolimus, interferon alfa or both in advanced renal-cell carcinoma: One plus one does not always equal two
por: Grover, S., et al.
Publicado: (2007)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

Open versus robotic radical cystectomy: Results from the 3-year follow-up of the RAZOR trial
por: Nagasubramanian, Santhosh
Publicado: (2020)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

The SMART trial; does it make us wiser in choosing between sirolimus in preference to cyclosporine – A postrenal transplant?
por: Mishra, Ankit
Publicado: (2021)

Partial nephrectomy for small renal tumors may prevent chronic kidney disease
por: Kumar, Rajeev
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_i9l33kj1me310mf8jtaiup752k